Sanofi is undergoing a significant leadership transition with Belén Garijo set to replace Paul Hudson as CEO, a change that will officially take effect after the general meeting on April 29, 2026.
This executive shift follows a period of significant stock market underperformance for the pharmaceutical company over the past year. The news has had an immediate impact on Sanofi's stock, which dropped nearly 5% in today's session, falling to 78.67 euros.
This price point is notably below both its 50-day and 200-day moving averages, signaling a weakening medium-term bullish momentum and confirming a southward-oriented fundamental trend. Over the last three months, the stock has seen an 11.66% decline.
In addition to the governance change, Sanofi recently completed the acquisition of Dynavax Technologies, expanding its vaccine portfolio. The company is also preparing for its first-quarter 2026 results publication on April 23, which will be the initial financial assessment under the new leadership.
Sanofi Shares Fall After CEO Change(current)
